

Titolo: Urothelial Cancer Update 2026: Meets the Guidelines, Challenges the Decisions

Sede e data: Torino-Aula Magna Dental School - Via Nizza, 2030, 10126 Torino - 18 settembre 2026

Responsabile Scientifico: Prof. Paolo Gontero

Provider ECM: Symposia Organizzazione Congressi Srl - ID 486

N. Accreditamento ECM: tbd

Ore formative: 7

Crediti ECM: tbd

Obiettivo formativo: Linee Guida - Protocolli - Procedure

Destinatari dell'iniziativa: N. 120 Medici Chirurghi specialisti in Urologia, chirurgia generale, anestesia e rianimazione, oncologia, radioterapia, radiodiagnostica, anatomia patologica

08.00 – 08.30: Registration

08.30: Welcome and introduction: why 2026 is a turning point in urothelial cancer (L. Tranchida – P. Cassoni – P. Fonio – P. Gontero - F. Soria)

09.00 – 11.00 Focus on NMIBC – Moderators: C. Scoffone, A. Volpe, G. Marra

Session 1: NMIBC in 2026: are we finally changing practice?

09.00 – 09.15 **Lecture:** Active surveillance for LG recurrent NMIBC: the time is now – R. Contieri
Discussion (5')

09.20 – 09.35 **Lecture:** Urinary markers in NMIBC: finally useful or still nearly there? – P. Mariappan
Discussion (5')

09.35 – 09.50 **Video-lecture:** ERBT: from clinical practice to robotic resection and beyond – J. Teoh
Discussion (5')

Session 2: BCG-naïve scenario

09.55 – 10.25 **Debate (with voting):** Combination therapies for BCG-naïve NMIBC: ready for prime time?

- Case presentation (5') – F. Lavagno
- Yes, in selected patients (10') – S. E. Rebuzzi
- No, not yet (10') – M. Moschini

Discussion (5')

Session 3: BCG-unresponsive scenario

10.30 – 10.45 **Lecture:** Selecting the right patient for bladder-sparing treatment – J. L Dominguez-Escrig

10.45 – 11.00 **Lecture:** Gemcitabine – Docetaxel combination: real option or evidence gap? – B. Pradere
Discussion (5')

11.05 - 11.25: **Round Table** Rethinking trial design in NMIBC: which endpoint for which clinical scenario? (P. Gontero, A. Antonelli, P. Giannatempo, A. Boni) – Moderator: F. Soria

11.25-11.50 **Coffee break**

11.50 – 13.10 Focus on UTUC – Moderators: C. Fiori, A. Antonelli, C. Ceruti

11.50 – 12.05 **Video-lecture:** New lasers for the endoscopic treatment of UTUC: how I choose – S. Proietti
Discussion (5')

12.10 – 12.25 **Lecture:** FDG PET/CT for UTUC staging: ready for broader clinical use? – S. Morbelli
Discussion (5')

12.30 – 12.45 **Video-lecture:** SP distal ureterectomy with LAA approach, a possible new standard? – P. Gontero
Discussion (5')

12.50 – 13.05 **Lecture:** FGFR3, HER2 and beyond: does molecular biology matter in daily UTUC practice? – E. Comperat
Discussion (5')

13.10 – 13.30 Keynote lecture: The evolving management of urothelial cancer: are the guidelines keeping pace with the evidence? – M. Ribal

13.30 – 14.20 **Lunch**

14.20 – 16.15 Focus on localized MIBC - Moderators: I. Depetris, M. Oderda, U. Ricardi

14.20 – 14.35 **Video-lecture:** SP Radical cystectomy: fact or fiction? – F. Soria
Discussion (5')

14.40 – 14.55 **Lecture:** Improving quality of life after radical cystectomy: what truly matters? – S. Albisinni
Discussion (5')

15.00 – 15.15 **Lecture:** 2024-2026: the revolution of perioperative treatment in MIBC – R. Filippi
Discussion (5')

15.20 – 15.35 **Video-lecture:** Uretero-ileal stenosis: how to prevent it, how to manage it– G. Simone
Discussion (5')

15.40 – 15.55 **Lecture:** Radiotherapy beyond TMT: where are we going? – G. Iorio

Discussion (5')

16.00 – 16.15 Focus on adjuvant therapy and metastatic disease - Moderators: B. Pradere, C. Ortega, M. Icardi

16.00 – 16.15 **Lecture:** Adjuvant therapy after radical cystectomy: when to intensify, when to de-escalate – P. Giannatempo
Discussion (5')

16.20 – 16.35 **Lecture:** Consolidative surgery after EV-P in oligometastatic disease: new frontier or selected opportunity? – A. Mari
Discussion (5')

16.40 – 16.55 **Lecture:** Metastatic disease: current standard of care and future directions – M. Tucci
Discussion (5')

17.00 Conclusions (P. Gontero, F. Soria)

ACRONIMI

BCG - Bacillus Calmette-Guérin
NMIBC - carcinoma alla vescica non muscolo-invasivo
TURB - Resezione Transuretrale della Vescica
MMR - Mismatch Repair (riparazione dei mismatch)
DNA - DeoxyriboNucleic Acid
CIS - Carcinoma In Situ
KSS - Kidney-Sparing Surgery
UTUC - Upper Urinary Tract Urothelial Cell Carcinoma
MIBC - muscle-invasive bladder cancer

RAZIONALE SCIENTIFICO

Il meeting “Urothelial Cancer Update 2026 meets the Guidelines, Challenges the Decisions” si rinnova come un'opportunità di approfondimento sulle ultime novità nella diagnosi, nel trattamento e nella gestione del tumore uroteliale, sia vescicale che dell'alta via urinaria.

Il convegno permetterà di approfondire la comprensione della biologia e della patogenesi del tumore uroteliale, nonché di acquisire conoscenze dettagliate sulle tecniche diagnostiche più recenti e sui marcatori urinari per la diagnosi e il follow up del tumore vescicale. Inoltre, anche alla luce delle recenti innovazioni in campo terapeutico, verranno approfonditi i trattamenti chirurgici, oncologici e radioterapici nell'ambito del tumore vescicale e dell'alta via urinaria, con particolare attenzione al ruolo attuale e dell'immunoterapia, sia nel tumore localizzato che in quello metastatico.

Anche in questa quinta edizione sarà protagonista il confronto con i principali portavoce delle Linee Guida europee nel settore.